文献速递腹部技术与安全US

QElaXto技术与Supersonic Imagine在慢性肝病肝脏硬度定量中的相关性

Correlation Between QElaXto Techniques and Supersonic Imagine for Liver Stiffness Quantification in Chronic Liver Disease.
PubMed 文献 · J Ultrasound Med · 2021-06-25

研究纳入235例无影响肝脏硬度合并症的代偿期慢性肝病患者(其中101例接受肝活检),评估p-QElaXto和2D-QElaXto与SSI 2D-SWE测量肝脏硬度的一致性,并以SSI为参考标准计算QElaXto技术诊断纤维化分期的特定阈值。2D-QElaXto与SSI的相关系数r=0.898,p-QElaXto与SSI的r=0.866,与SSI相比平均差值分别为-1.3 kPa和-0.6 kPa。非HBV相关慢性肝病中诊断≥F2、≥F3和F4的阈值:2D-QElaXto分别为5.5、8.0、10.6 kPa,p-QElaXto分别为6.1、8.1、11.7 kPa。

要点

  • 2D-QElaXto与SSI的肝脏硬度相关系数r=0.898,p-QElaXto与SSI为r=0.866。
  • 与SSI相比,2D-QElaXto平均差值-1.3 kPa,p-QElaXto平均差值-0.6 kPa。
  • 非HBV相关慢性肝病诊断≥F2、≥F3、F4阈值:2D-QElaXto为5.5、8.0、10.6 kPa;p-QElaXto为6.1、8.1、11.7 kPa。

核心结论

  • QElaXto技术与SSI在肝脏硬度测量中的相关性很好,研究首次为两种QElaXto技术在非HBV相关慢性肝病中确定了纤维化分期的阈值。

研究设计与样本

  • 研究纳入235例无影响肝脏硬度合并症的代偿期慢性肝病患者,其中101例同时接受肝活检;以SuperSonic Imagine 2D-SWE为参考标准,采用Pearson相关系数和Bland-Altman分析评估设备间一致性,采用受试者工作特征分析计算阈值。

诊断标准与关键数值

  • 非HBV相关慢性肝病中诊断纤维化≥F2、≥F3、F4的阈值:2D-QElaXto分别为5.5、8.0、10.6 kPa,p-QElaXto分别为6.1、8.1、11.7 kPa。

临床应用与阅片要点

  • 在非HBV相关慢性肝病中可参考上述QElaXto技术特异性阈值进行纤维化分期,不宜直接套用SSI的阈值。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Intersystem variability in liver stiffness (LS) quantification with ultrasound shear wave elastography (SWE) precludes direct comparison of results obtained with different equipment. The aim of this study was to investigate the agreement between point-SWE and 2-dimensional-SWE with Esaote-MyLab 9 (p-QElaXto and 2D-QElaXto, respectively) and 2D-SWE with SuperSonic Imagine (SSI) in order to assess specific LS thresholds for fibrosis staging with QElaXto techniques, using SSI as a reference standard.

METHODS: A total of 235 compensated chronic liver disease (CLD) patients without comorbidities potentially affecting LS were enrolled in the study. Among them, 101 patients underwent also liver biopsy. Agreement between the equipment was assessed with Pearson coefficient and Bland-Altman analysis, while cut-off values were calculated with receiver operating characteristics analysis.

RESULTS: Correlation between 2D-QElaXto and p-QElaXto with SSI resulted very good (r = 0.898 and r = 0.866), especially in precirrhotic stages, with a mean difference between LS values of -1.3 kPa for 2D-QElaXto and -0.6 kPa for p-QElaXto compared with SSI. Cut-off thresholds for diagnosing fibrosis ≥F2, ≥F3, and F4 in non-HBV-related CLD were, respectively, 5.5, 8.0, and 10.6 kPa for 2D-QElaXto and 6.1, 8.1, and 11.7 kPa for p-QElaXto. All three SWE techniques were effective in differentiating significant fibrosis ≥F2 from mild or absent fibrosis in the subgroup of patients submitted to biopsy and showed good feasibility.

CONCLUSIONS: Correlation between QElaXto techniques and SSI in LS measurements is very good. Our study identifies for the first time cut-off thresholds for fibrosis staging in non-HBV-related CLD using two QElaXto techniques.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Garcovich M, Faccia M, Di Stasio E, et al. Correlation Between QElaXto Techniques and Supersonic Imagine for Liver Stiffness Quantification in Chronic Liver Disease. J Ultrasound Med. 2021. PMID: 34170033. doi:10.1002/jum.15767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。